Cover Image

EGFR T790M Mutation Detection in Patients With Non-Small Cell Lung Cancer After First Line EGFR TKI Therapy: Summary of Results in a Three-Year Period and a Comparison of Commercially Available Detection Kits

EGFR mutation in non-small cell lung cancer (NSCLC) offers a potential therapeutic target for tyrosine kinase inhibitor (TKI) therapy. The majority of these cases, however eventually develop therapy resistance, mainly by acquiring EGFR T790M mutation. Recently, third-generation TKIs have been introd...

Full description

Saved in:

Bibliographic Details
Main Authors:	Eszter Bencze (Author), Krisztina Bogos (Author), Andrea Kohánka (Author), László Báthory-Fülöp (Author), Veronika Sárosi (Author), Erzsébet Csernák (Author), Nóra Bittner (Author), Zsombor Melegh (Author), Erika Tóth (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
by: Luwei Han, et al.
Published: (2021)

EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
by: Chenguang Li, et al.
Published: (2018)

Stevens-Johnson syndrome induced by toripalimab in a previously EGFR-TKI-treated advanced lung adenocarcinoma patient harboring EGFR mutations 19 del/T790M/C797S in trans and cis: a case report
by: Yang Chen, et al.
Published: (2023)

Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
by: Jianghua Ding, et al.
Published: (2024)

Osteosarcomatous Differentiation in Rebiopsy Specimens of Pulmonary Adenocarcinoma with EGFR-TKI Resistance
by: Hyein Ahn, et al.
Published: (2018)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
by: Xiaoyu Qian, et al.
Published: (2022)

The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC
by: Wang Z, et al.
Published: (2022)

Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports
by: Yue Zeng, et al.
Published: (2022)

EGFR-mutated pulmonary adenocarcinoma with concurrent PIK3CA mutation, and with acquired RET fusion and EGFR T790M mutation after afatinib therapy
by: Minhye Kim, et al.
Published: (2021)

In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features
by: Xiang M, et al.
Published: (2013)

Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
by: Wei-Yun Lai, et al.
Published: (2014)

Deciphering the Dynamics of EGFR-TKI Resistance in Lung Cancer: Insights from Bibliometric Analysis
by: Zhou Y, et al.
Published: (2024)

Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib
by: Yaming Liu, et al.
Published: (2021)

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
by: Yamin Shu, et al.
Published: (2022)

A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma
by: Muammar Fawwaz, et al.
Published: (2021)

Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients
by: Mariella Dono, et al.
Published: (2019)

Chinese Herbal Medicine Combined With EGFR-TKI in EGFR Mutation-Positive Advanced Pulmonary Adenocarcinoma (CATLA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
by: Lijing Jiao, et al.
Published: (2019)

Pre-treatment Neutrophil-to-Lymphocyte Ratio significantly affects progression free survival in positive EGFR mutation advanced lung adenocarcinoma with EGFR-TKI treatment in Bali, Indonesia
by: Widiasari Ni Putu Ayu, et al.
Published: (2023)

Discovery of a Novel, Selective and Irreversible Inhibitor (Abivertinib) of Mutated EGFR and T790M-induced Resistance for the Treatment of NSCLC
by: Long Mao, et al.
Published: (2020)

Dysregulation and detection methods of EGFR in oral cancer. A narrative review.
by: Carolina Somarriva, et al.
Published: (2016)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFRWT, EGFRT790M, and EGFRL858R)
by: Mahmoud G. Abo Al-Hamd, et al.
Published: (2023)

Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR
by: Francesca Foschi, et al.
Published: (2023)

Chromosomal Copy Number Variation Predicts EGFR-TKI Response and Prognosis for Patients with Non-Small Cell Lung Cancer
by: He H, et al.
Published: (2023)

Design and Synthesis of New Hydantoin Acetanilide Derivatives as Anti-NSCLC Targeting EGFR<sup>L858R/T790M</sup> Mutations
by: Moamen A. Hassanin, et al.
Published: (2022)

Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review
by: Xiaofei Gu, et al.
Published: (2024)

Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents
by: Xuanhong Jin, et al.
Published: (2024)

Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR‐mutated lung cancer treated with the first‐/second‐generation tyrosine kinase inhibitors
by: Michael Menzel, et al.
Published: (2024)

Targeting Nicotinamide N-Methyltransferase and miR-449a in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer Cells
by: Duc-Hiep Bach, et al.
Published: (2018)

Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients
by: I. H. Bartelink, et al.
Published: (2022)

Apigenin Combined With Gefitinib Blocks Autophagy Flux and Induces Apoptotic Cell Death Through Inhibition of HIF-1α, c-Myc, p-EGFR, and Glucose Metabolism in EGFR L858R+T790M-Mutated H1975 Cells
by: ZiSheng Chen, et al.
Published: (2019)

AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer
by: Geunho Choi, et al.
Published: (2021)

Liquid Biopsy in <i>EGFR</i>-Mutated Advanced NSCLC from T790M to <i>MET</i> Amplification: Clinical Implications and Possibilities in the Resistance Setting
by: Luigi Della Gravara, et al.
Published: (2023)

Detection of EGFR Mutations From Plasma of NSCLC Patients Using an Automatic Cartridge-Based PCR System
by: Simon Heeke, et al.
Published: (2021)

Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients
by: Wei Wu, et al.
Published: (2020)

Natural product manoalide promotes EGFR-TKI sensitivity of lung cancer cells by KRAS-ERK pathway and mitochondrial Ca2+ overload-induced ferroptosis
by: Yinyun Ni, et al.
Published: (2023)

Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial-Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells
by: Pedro Barrios-Bernal, et al.
Published: (2022)

A case of Ph+ acute lymphoblastic leukemia and EGFR mutant lung adenocarcinoma synchronous overlap: may one TKI drug solve two diseases?
by: Qi Zhang, et al.
Published: (2024)

Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer
by: Brian J. Thomas, et al.
Published: (2023)

EGFR-Targeted Photodynamic Therapy
by: Luca Ulfo, et al.
Published: (2022)

EGFR Mutation in Nasopharyngeal Carcinoma
by: Evren Uzun, et al.
Published: (2022)